Sinekod syrup, 100ml

Symptomatic treatment of dry coughs of various etiologies:

• suppression of cough in the pre- and postoperative period,

• during surgical interventions,

• bronchoscopy,

• with whooping cough.

Inside, before meals.
Children from 3 to 6 years old - 5 ml 3 times a day;
6-12 years old - 10 ml 3 times a day;
12 years and older - 15 ml 3 times a day;
adults - 15 ml 4 times a day.
Use the measuring cap (supplied).

Syrup (vanilla) in the form of a colorless transparent liquid with a vanilla smell.

1 ml

butamirate citrate 1.5 mg

Excipients: sorbitol solution 70% m / m - 40.5% m / v., Glycerol - 29% m / v., Sodium saccharinate - 0.06% m / v., Benzoic acid - 1.115% m / v., Vanillin - 0.06 % m / v, ethanol 96% v / v - 0.25% m / v., Sodium hydroxide 30% m / m - 0.031% m / v., Water - up to 100 ml.

• Hypersensitivity to the components of the drug;

• children under 3 years old (for syrup);

• I trimester of pregnancy;

• lactation period;

• intolerance to fructose (the drug contains sorbitol);

• With care: II and III trimesters of pregnancy. Due to the presence of ethyl alcohol in the composition of the drug, use with caution in patients with a tendency to develop drug dependence, with liver diseases, alcoholism, epilepsy, brain diseases, in pregnant women (II and III trimesters) and children.

Pharmacological properties

Butamirate, the active substance of the Sinekod drug, is a centrally acting antitussive agent, neither chemically nor pharmacologically related to opium alkaloids. It has an expectorant, moderate bronchodilatory and anti-inflammatory effect, has a direct effect on the cough center, improves spirometry (reduces airway resistance) and blood oxygenation.

Pharmacokinetics
Butamirate is rapidly and completely absorbed when taken orally. After taking 150 mg of butamirate, the maximum plasma concentration of the main metabolite (2-phenylbutyric acid) is reached after about 1.5 hours and is 6.4 ?g / ml. The half-life is 6 hours. When the drug is reappointed, its concentration in the blood remains linear and no cumulation is observed. Hydrolysis of butamirate, initially to 2-phenylbutyric acid and diethylaminoethoxyethanol, begins in the blood. These metabolites also have antitussive activity. Like butamirate, metabolites have an almost maximum (about 95%) degree of binding to plasma proteins, which causes, among other things, their long half-life from plasma. Metabolites are excreted mainly in the urine,moreover, acidic metabolites are largely associated with glucuronic acid.

Application during pregnancy and lactation

In studies conducted in animals, no adverse effects on the fetus were noted. No controlled studies have been conducted in pregnant women. In this regard, Sinekod should not be used in the first trimester of pregnancy. In the II and III trimesters, the use of Sinekod is possible taking into account the benefits to the mother and the potential risk to the fetus. Given the lack of data on the excretion of the active substance in breast milk, the appointment of Sinekod during lactation is not recommended.

Side effects
Skin rash, nausea, diarrhea, dizziness (frequency less than 1%), allergic reactions.

Overdose
Symptoms: drowsiness, nausea, vomiting, diarrhea, loss of balance and decreased blood pressure.

Treatment: activated charcoal, saline laxatives, maintaining the function of the cardiovascular and respiratory systems.

Interaction with other medicinal products
No drug interactions have been described for butamirate.

special instructions

The syrup contains saccharin and sorbitol as sweeteners, therefore it can be prescribed for patients with diabetes mellitus.